Caeptis Therapeutics announces a 1-for-20 reverse stock split, effective December 31st.

Caeptis Therapeutics (NASDAQ: COEP) will execute a 1-for-20 reverse stock split on December 31st, announced on December 27th. Share adjustments will occur after the market closes on December 30th. The company, focusing on cancer cell therapy, develops treatments for multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia.

3 months ago
5 Articles